DEFERASIROX TAB,SUSP,ORAL
Clinical Criteria Summary
Exclusion Criteria
- Creatinine clearance <40 mL/min/1.73m2
- Severe (Child-Pugh C) hepatic impairment
- Terminal high-risk Myelodysplastic Syndrome (MDS-excess blasts)
- Unmanageable CYP2C8, CYP1A2, UGT, bile sequestrant, or aluminum-containing antacid drug interactions
- Baseline ophthalmology exam not completed
- Known hypersensitivity to deferasirox or any of its components
- Breastfeeding
Inclusion Criteria
- Chronic iron overload due to red blood cell transfusion dependence
- Chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes, and a liver iron concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L
Additional Inclusion Criteria
- Care is provided by a VA/VA Community Care oncology or hematology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Pregnancy Counseling Requirement
- For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective non-hormonal contraception during therapy